Integrating Serum Neurofilament Light Chain Into Amyotrophic Lateral Sclerosis Diagnostic Criteria - PubMed
4 days ago
- #biomarker
- #diagnostic criteria
- #ALS
- Serum neurofilament light chain (NfL) is a promising diagnostic biomarker for differentiating ALS from clinical mimics.
- The study assessed integrating serum NfL into current ALS diagnostic criteria to enhance diagnostic certainty.
- 43 patients with a provisional ALS diagnosis were included, with 62.8% progressing to definite ALS at follow-up.
- Elevated serum NfL (cutoff 38 pg/mL) was found in 79.1% of the total cohort and 88.9% of those progressing to definite ALS.
- Integrating serum NfL with Gold Coast Criteria (GCC) increased the odds of identifying patients likely to progress to definite ALS by tenfold.
- Serum NfL complements current ALS diagnostic criteria and improves early identification and diagnostic certainty.
- Larger multicenter, prospective studies are needed to confirm these findings.